Abstract: A method for inducing cell death in neoplastic cells, includes the step of administering a compound of formula I or a pharmaceutically acceptable salt thereof, as a primary chemotherapeutic agent or substantially contemporaneously with chemotherapy, to a patient having multidrug-resistant neoplastic cells, in an amount sufficient to induce cell death in the neoplastic cells: ##STR1## where R.sup.1 is hydroxyl, C1-4 alkoxyl, C1-4 alkylcarboxyloxymethoxyl, phenyl C1-2 alkylamino group, 2,5-pyrrolidinedione-1-alkoxyl (C1-4), or ##STR2## wherein X.sup.1 is a chemical bond or C1-2 alkylene, X.sup.2 is hydrogen or carboxyl forming a 5-membered ring with X.sup.1 when X.sup.1 is methylene, X.sup.3 is hydrogen or C1-2 alkyl, X.sup.4 is hydrogen or C1-2 alkyl, or X.sup.3 and X.sup.4 together form a 5-membered ring, in which at least one of X.sup.2, X.sup.3, and X.sup.4 is hydrogen,R.sup.2 is C3-4 alkyl, R.sup.3 is C1-4 alkyl, ##STR3## in which n is an integer of 0 to 3.

Abstract: A method for inducing cell death in neoplastic cells, includes the step of administering a compound of formula I or a pharmaceutically acceptable salt thereof, as a primary chemotherapeutic agent or substantially contemporaneously with chemotherapy, to a patient having multidrug-resistant neoplastic cells, in an amount sufficient to induce cell death in the neoplastic cells: ##STR1## where R.sup.1 is hydroxyl, C1-4 alkoxyl, C1-4 alkylcarboxyloxymethoxyl, phenyl C1-2 alkylamino group, 2,5-pyrrolidinedione-1-alkoxyl (C1-4), or ##STR2## wherein X.sup.1 is a chemical bond or C1-2 alkylene, X.sup.2 is hydrogen or carboxyl forming a 5-membered ring with X.sup.1 when X.sup.1 is methylene, X.sup.3 is hydrogen or C1-2 alkyl, X.sup.4 is hydrogen or C1-2 alkyl, or X.sup.3 and X.sup.4 together form a 5-membered ring, in which at least one of X.sup.2, X.sup.3, and X.sup.4 is hydrogen,R.sup.2 is C3-4 alkyl, R.sup.3 is C1-4 alkyl, ##STR3## in which n is an integer of 0 to 3.

Abstract: A method for inducing cell death in neoplastic cells, includes the step of administering a compound of formula I or a pharmaceutically acceptable salt thereof, as a primary chemotherapeutic agent or substantially contemporaneously with chemotherapy, to a patient having multidrug-resistant neoplastic cells, in an amount sufficient to induce cell death in the neoplastic cells: ##STR1## where R.sup.1 is hydroxyl, C1-4 alkoxyl, C1-4 alkylcarboxyloxymethoxyl, phenyl C1-2 alkylamino group, 2,5-pyrrolidinedione-1-alkoxyl (C1-4), or ##STR2## wherein X.sup.1 is a chemical bond or C1-2 alkylene, X.sup.2 is hydrogen or carboxyl forming a 5-membered ring with X.sup.1 when X.sup.2 is methylene, X.sup.3 is hydrogen or C1-2 alkyl, X.sup.4 is hydrogen or C1-2 alkyl, or X.sup.3 and X.sup.4 together form a 5-membered ring, in which at least one of X.sup.2, X.sup.3, and X.sup.4 is hydrogen,R.sup.2 is C3-4 alkyl, R.sup.3 is C1-4 alkyl, ##STR3## in which n is an integer of 0 to 3.

Abstract: Various 3-substituted cyproheptadine derivatives are useful in the treatment of infection by Plasmodium falciparum and in the treatment of malaria either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with antimalarial agents or compounds. Methods of treating malaria and methods of treating infection by Plasmodium falciparum are also described.

Abstract: Compounds having the formula: ##STR1## wherein R.sup.1 is --NH(C.dbd.O)OR.sup.5, --NH(C.dbd.NH)NH.sub.2 or --NH(C.dbd.N--NO.sub.2)HN.sub.2 ; R.sup.2 is hydrogen, C.sub.1-8 alkyl or C.sub.6-8 aryl; n is 2 to 6; and R.sup.5 is hydrogen,C.sub.1-8 alkyl, C.sub.6-8 aryl, or C.sub.7-8 alkaryl; are disclosed in addition to methods to employ such compounds to induce migration of endothelial cells into denuded areas of vessel lining and to treat malignant hypercalcemia.